BioCentury
ARTICLE | Company News

Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, GlaxoSmithKline cancer, cardiology, endocrine/metabolic news

June 22, 2015 7:00 AM UTC

Avalon Ventures and GlaxoSmithKline launched three build-to-buy companies, Adrenergics, CadheRx and Calporta, each with $3 million in series A funding and $7 million in R&D support. The companies will...